Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joel G Rurik

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Nature Cardiovascular Research|March 28, 2025
Inflammatory CD248<sup>+</sup> activated fibroblasts are a potential therapeutic target in ischemic heart diseaseJoel G Rurik
DNA and Cell Biology|April 21, 2022
Uniting Disciplines to Develop Therapeutics: Targeted mRNA Lipid Nanoparticles Reprogram the Immune System <i>In Vivo</i> to Treat Heart DiseaseJoel G Rurik, Jonathan A Epstein
Circulation Research|May 27, 2021
Immune Cells and Immunotherapy for Cardiac Injury and RepairJoel G Rurik, Haig Aghajanian, Jonathan A Epstein
Nature Metabolism|March 1, 2022
CAR-based therapies: opportunities for immuno-medicine beyond cancerHaig Aghajanian, Joel G Rurik, Jonathan A Epstein
Immunity|April 2, 2026
Memory T cell aging and rejuvenationSarah Adamo, Joel G Rurik, Claire E Gustafson, et al.
The Journal of Biological Chemistry|October 5, 2017
Proteolytic degradation of regulator of G protein signaling 2 facilitates temporal regulation of G<sub>q/11</sub> signaling and vascular contractionStanley M Kanai, Alethia J Edwards, Joel G Rurik, et al.
Journal of Developmental Biology|January 16, 2016
Pbx4 is Required for the Temporal Onset of Zebrafish Myocardial DifferentiationRobert M Kao, Joel G Rurik, Gist H Farr, et al.
Iscience|March 9, 2026
From byproduct to biotherapeutic: Comparative study of buffy coats and leukoreduction system chambers for NK cell-based immunotherapiesMaximiliane Tietze, Maria Schuldt, Martina Wohsmann, et al.
Molecular Cell|September 15, 2022
Tissue-specific Grb10/Ddc insulator drives allelic architecture for cardiac developmentAimee M Juan, Yee Hoon Foong, Joanne L Thorvaldsen, et al.
Biorxiv : the Preprint Server for Biology|March 10, 2025
In vivo anti-FAP CAR T therapy reduces fibrosis and restores liver homeostasis in metabolic dysfunction-associated steatohepatitisChittampalli N Yashaswini, Bruno Cogliati, Tianyue Qin, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Nature Cardiovascular Research|March 28, 2025
Inflammatory CD248<sup>+</sup> activated fibroblasts are a potential therapeutic target in ischemic heart diseaseJoel G Rurik
DNA and Cell Biology|April 21, 2022
Uniting Disciplines to Develop Therapeutics: Targeted mRNA Lipid Nanoparticles Reprogram the Immune System <i>In Vivo</i> to Treat Heart DiseaseJoel G Rurik, Jonathan A Epstein
Circulation Research|May 27, 2021
Immune Cells and Immunotherapy for Cardiac Injury and RepairJoel G Rurik, Haig Aghajanian, Jonathan A Epstein
Nature Metabolism|March 1, 2022
CAR-based therapies: opportunities for immuno-medicine beyond cancerHaig Aghajanian, Joel G Rurik, Jonathan A Epstein
Immunity|April 2, 2026
Memory T cell aging and rejuvenationSarah Adamo, Joel G Rurik, Claire E Gustafson, et al.
The Journal of Biological Chemistry|October 5, 2017
Proteolytic degradation of regulator of G protein signaling 2 facilitates temporal regulation of G<sub>q/11</sub> signaling and vascular contractionStanley M Kanai, Alethia J Edwards, Joel G Rurik, et al.
Journal of Developmental Biology|January 16, 2016
Pbx4 is Required for the Temporal Onset of Zebrafish Myocardial DifferentiationRobert M Kao, Joel G Rurik, Gist H Farr, et al.
Iscience|March 9, 2026
From byproduct to biotherapeutic: Comparative study of buffy coats and leukoreduction system chambers for NK cell-based immunotherapiesMaximiliane Tietze, Maria Schuldt, Martina Wohsmann, et al.
Molecular Cell|September 15, 2022
Tissue-specific Grb10/Ddc insulator drives allelic architecture for cardiac developmentAimee M Juan, Yee Hoon Foong, Joanne L Thorvaldsen, et al.
Biorxiv : the Preprint Server for Biology|March 10, 2025
In vivo anti-FAP CAR T therapy reduces fibrosis and restores liver homeostasis in metabolic dysfunction-associated steatohepatitisChittampalli N Yashaswini, Bruno Cogliati, Tianyue Qin, et al.
Pageof 2